8 Jun 2018 07:00
8 June 2018 07:00 BST
Â
Director Declaration
Â
AstraZeneca PLC (the Company) today announced that Philip Broadley, a Non-Executive Director of the Company, was appointed as a director of Stallergenes Greer plc following the conclusion of its Annual General Meeting of Shareholders with effect from 7 June 2018.
Â
This announcement is made pursuant to Listing Rule 9.6.14 R (2).
Â
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Â
For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
Â
Media Relations | ||
Karen Birmingham | UK/Global | +44 203 749 5634 |
Rob Skelding | UK/Global | +44 203 749 5821 |
Matt Kent | UK/Global | +44 203 749 5906 |
Gonzalo Viña | UK/Global | +44 203 749 5916 |
Jacob Lund | Sweden | +46 8Â 553Â 260 20 |
Michele Meixell | US | +1 302 885 2677 |
Investor Relations | ||
Thomas Kudsk Larsen | Â Â | +44 203 749 5712 |
Josie Afolabi | +44 203 749 5631 | |
Craig Marks | Finance; Fixed Income; M&A | +44 7881 615 764 |
Henry Wheeler | Oncology | +44 203 749 5797 |
Mitchell Chan | Oncology; Other | +1 240 477 3771 |
Christer Gruvris | Brilinta; Diabetes | +44 203 749 5711 |
Nick Stone | Respiratory; Renal | +44 203 749 5716 |
Jennifer Kretzmann | Retail Investors | +44 203 749 5824 |
US toll-free | +1 866 381 7277 | |
Adrian KempCompany Secretary
AstraZeneca PLC
Astrazeneca (AZN)